At LipoScience, we have a passion for improving patient care. That passion is embodied in our nuclear magnetic resonance (NMR) diagnostic technology. Designed to identify and quantify lipoproteins and small molecule metabolites, our proprietary process provides precise, clear, and actionable answers that help physicians and patients proactively manage cardiovascular disease and diabetes. The NMR LipoProfile® test, our first proprietary test, is an FDA-cleared blood test that directly quantifies LDL particles. To date, more than 11 million NMR LipoProfile tests have been ordered.
The Vantera® Clinical Analyzer is the first FDA-cleared platform that utilizes NMR technology. Its ease of use and quick turnaround time helps maximize efficiency and throughput in the clinical laboratory.
As LipoScience looks to the future, we are focused on driving innovation for personalized diagnostics through NMR technology. We are developing assays to address a broad range of diseases including cardiovascular, metabolic disorders and oncology. Because the NMR spectrum is information rich, the potential for LipoScience to be at the forefront of diagnostic breakthroughs is greater now than ever.
Headquartered in Raleigh, North Carolina, LipoScience employs approximately 200 employees in the United States. The Company's Common Stock is listed on the NASDAQ Global Market under the trading symbol "LPDX".